Rapid release of open coronavirus sequence data will help guide COVID-19 public health response, drive innovation and discovery, and advance understanding of this and future pandemics.
The SARS-CoV-2 Sequencing for Public Health Emergency Response, Epidemiology and Surveillance (SPHERES) consortium, which will greatly expand the use of whole genome sequencing (WGS) of the COVID-19 virus. Consortium members include Northern Arizona University, TGen, and the State of Ariona.
Funding Will Support Commercialization of DROWZLE® PRO, the First FDA-Cleared Digital Home Sleep Test, and Consumer Sleep Health PlatformContinue reading
Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 TreatmentContinue reading
The Medtronic COVID-19 Care Evaluation and Monitoring Solution provides in-home evaluation, remote monitoring, and care escalation support.
TUCSON, Ariz., April 30, 2020 — Tucson-based Critical Path Institute (C-Path) today announced the appointment of two new members to its Board of Directors: James W. Newman, CPA, former Executive Chairman of Victory Pharma, Inc. and Tomas Salmonson, Ph.D., M.Sc., former Chair of the Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency (EMA).
VLA15 is the only active Lyme disease vaccine program in clinical development today, and covers six serotypes that are prevalent in North America and Europe. The investigational multivalent protein subunit vaccine, VLA15, targets the outer surface protein A (OspA) of Borrelia, an established mechanism of action for a Lyme disease vaccine. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick.Continue reading
On April 29, 2020, Daniel O’Day, Chairman & CEO, Gilead Sciences shared an Open Letter following the official press release containing data on Remdesivir and COVID-19.
“The results from the global, placebo-controlled trial run by the National Institute of Allergy and Infectious Diseases (NIAID) are positive. They show that patients with COVID-19 who received remdesivir recovered faster than similar patients who received placebo” O’Day writes. “There is still more work to do and remdesivir has not been approved, but all of us at Gilead are humbled by what these promising results might mean for patients. After years of research and hard work on remdesivir, there is relief and gratitude among our teams today that their efforts have been so worthwhile.”
Study Demonstrates Similar Efficacy with 5- and 10-Day Dosing Durations of RemdesivirContinue reading
Dr. Theresa Cullen is the new Pima County Public Health Director, effective June 1. Dr. Cullen has had a distinguished career as a public health physician, including retiring as a Public Health Service Officer from the federal government with the rank of Rear Admiral and Assistant U.S. Surgeon General.